Montag, 19. April 2021
Navigation öffnen
Anzeige:
Lonsurf
 
JOURNAL ONKOLOGIE – STUDIE
BIMI

Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)

Rekrutierend

NCT-Nummer:
NCT04720144

Studienbeginn:
Oktober 2020

Letztes Update:
09.02.2021

Wirkstoff:
-

Indikation (Clinical Trials):
Infection, Communicable Diseases, Hematologic Neoplasms, Hematologic Diseases

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Centre Hospitalier Universitaire Vaudois

Collaborator:
-

Studienleiter

Frederic Lamoth
Principal Investigator
Centre Hospitalier Universitaire Vaudois

Kontakt

Studienlocations
(3 von 8)

Alle anzeigen

Studien-Informationen

Brief Summary:

Invasive mold infections (IMI) mainly affect patients with hematologic malignancies receiving

intensive chemotherapy or after hematopoietic stem cell transplantation (HSCT). Prolonged

neutropenia after remission induction chemotherapy (>10 days duration) and continuous

immunosuppression in the context of prevention or therapy of graft versus host disease (GVHD)

for HSCT recipients (first 100 days post-transplantation and thereafter if GVHD is present)

are considered as periods at high risk of IMI.

Posaconazole prophylaxis is prescribed according to current guidelines to reduce the

occurrence of IMI. Nevertheless, breakthrough IMI (bIMI), i.e. IMI occurring under

mold-active prophylaxis, are still observed.

The investigators hypothesized that the epidemiology of bIMI (under posaconazole prophylaxis)

differs from that of IMI occurring in the absence of mold-active antifungal prophylaxis.

Because bIMI are rare events since the introduction of posaconazole prophylaxis,

epidemiological data of bIMI are scarce.

This study aims to i) describe the epidemiology, clinical features, treatment and outcome of

bIMI, ii) assess the causes of bIMI, iii) determine potential risk factors associated with

the developllement of bIMI iv) assess the impact of bIMI on overall mortality.

Design

Retrospective and prospective, observational, case-control, multicenter, international study.

The retrospective part will enroll previously identified bIMI cases and control cases (1:2)

over the last five years: October 1st 2015 to September 30st 2020.

The prospective part will enroll bIMI cases and control cases (1:2) occurring over a two-year

period: October 1st 2020 to September 30st 2022.

Setting

The aim is to enroll 10 to 15 European centers with dedicated units for hematologic cancer

patients. Currently, six centers have confirmed their participation (from Switzerland and

Germany).

Study Population

Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole

prophylaxis during induction, consolidation or re-induction chemotherapy or after HSCT.

Cases : patients receiving posaconazole prophylaxis for at least 7 days and diagnosed with

bIMI proven or probable according to EORTC-MSGERC.

Controls: patients receiving posaconazole prophylaxis for at least 7 days, without diagnosis

of bIMI possible, probable or proven according to EORTC-MSGERC.

The objective is to enroll about 100 bIMI cases and 200 controls.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Cases:

Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole

prophylaxis (oral tablets or IV administration) for:

i) Induction, consolidation or re-induction chemotherapy for acute leukemia or

myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10

days)

OR

ii) Allogeneic hematopoietic stem cell transplant recipients during the

post-transplantation phase (100-day post-transplantation) or later in case of intensified

immunosuppression for moderate to severe graft vs host disease (GVHD).

AND

iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSG classification

(10) while on continuous posaconazole prophylaxis for at least 7 days.

- Controls:

For each bIMI case, we will include 2 control cases fulfilling the following criteria:

i) Receiving continuous posaconazole prophylaxis for at least 7 days

ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSG classification

(10) during the entire hospital stay.

And matched to bIMI cases according to the following criteria:

iii) Hospitalization in the same ward within the same year (+/- 12 months interval)

iv) Same underlying condition related to hematologc cancer: a) HSCT within 100 days

post-engraftment, b) HSCT > 100 days post-engraftment with intensified immunosuppressive

regimen for severe GVHD, c) induction chemotherapy for acute myeloid or lymphoid leukemia,

or myelodysplastic syndrome, d) other hematologic disorders (e.g. aplastic anemia) with

prolonged neutropenia and/or immunosuppressive regimen.

Exclusion Criteria:

- Patients with a diagnosis of possible IMI according to the EORTC-MSG classification.

- Patients with a positive fungal biomarker in serum (e.g. galactomannan or beta-glucan)

in the absence of clinical or radiological criteria of IMI according to the EORTC-MSG

classification.

Studien-Rationale

Primary outcome:

1. Epidemiological description of bIMI (Time Frame - At inclusion):
Assessment of the cause of bIMI (intrinsically resistant mold pathogen vs susceptible mold pathogen but insufficient posaconazole serum concentration vs unknown) Description of clinical features, treatment and outcome of bIMI

2. Assessment of the risk factors of bIMI (Time Frame - At inclusion):
• Univariate and multivariate analyses of the parameters associated with an increased risk of bIMI (in particular, the association of a threshold of posaconazole concentration and bIMI) by comparison of bIMI cases with controls (posaconazole prophylaxis and no bIMI)

Secondary outcome:

1. Assessment of the impact of bIMI on overall mortality (Time Frame - 6 weeks and 12 weeks after inclusion):
• Comparison of mortality rate (6 and 12 weeks) between bIMI and control cases.

2. Assessment of factors influencing outcomes of bIMI (Time Frame - 6 weeks and 12 weeks after inclusion):
• Univariate and multivariate analysis of predictors of mortality (6 and 12 weeks) among bIMI cases.

Studien-Arme

  • bIMI cases
    Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for: i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD). AND iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days.
  • Controls
    For each bIMI case, we will include 2 control cases fulfilling the following criteria: i) Receiving continuous posaconazole prophylaxis for at least 7 days ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Brustkrebsmonat: Antihormonelle Therapie mit Nebenwirkungen
Brustkrebsmonat%3A+Antihormonelle+Therapie+mit+Nebenwirkungen
© LIGHTFIELD STUDIOS - stock.adobe.com

Etwa zwei Drittel aller bösartigen Brusttumore wachsen hormonabhängig. Weibliche Hormone wie das Östrogen lösen in den Tumorzellen einen Wachstumsreiz aus. Um das zu verhindern und das Rückfallrisiko zu senken, erhalten viele Brustkrebspatientinnen nach einer Operation zur Entfernung des Tumors über mehrere Jahre eine antihormonelle Therapie. Experten stufen die Begleiterscheinungen der Therapie zwar als weniger...